In this issue:
Luspatercept vs. epoetin alfa in lower-risk MDS
Clinical outcomes of COVID-19 plus haematological disease
Pembrolizumab after autologous SCT in T-cell NHL
Tislelizumab for relapsed/refractory mature T- and NK-cell neoplasms
Tacrolimus-methotrexate vs. tacrolimus-reduced methotrexate-mycophenolate for GVHD prevention
CPX-351 vs. FLAG-Ida for adverse karyotype AML and high-risk MDS
Front-line rituximab vs. obinutuzumab for follicular lymphoma
Score to predict severe CRS after CAR T-cell therapy
Sustained C1s inhibition with sutimlimab in cold agglutinin disease
Iron overload/chelation with deferasirox in severe aplastic anaemia after allogeneic SCT
Please login below to download this issue (PDF)